Fevara Strengthens Brazilian Footprint with Strategic Production Facility Acquisition

There is a deferred consideration due in March 2027 that depends on the performance of the acquired mineral distribution business during 2026. In other words, it functions like an earn-out, and the company states it will be self-funding. The transaction was funded from the Group’s existing resources.

Item	Detail
Initial consideration	£4.3 million
Freehold property component	£4.0 million
Operating business component	£0.3 million
Deferred consideration	Dependent on 2026 performance, due March 2027, self-funding (amount not disclosed)
Funding source	Existing resources
Location	Northern São Paulo State, Brazil
Production start	Expected Q2 next year
Initial distribution footprint	São Paulo State and Mato Grosso do Sul, with Goiás and Minas Gerais to follow
Target market access	Approximately 100 million head of beef cattle across targeted states
Brazil cattle population	More than 200 million

Strategic logic: a bigger stage for high margin products

Fevara’s core proposition is research-proven livestock supplements designed for extensive grazing systems. Shifting production onshore in Brazil should support the rollout of its higher margin lines and tailor formulations to local conditions, which can improve customer uptake. It also strengthens the Group’s control over quality, lead times and distribution in a market with scale that few others can match.

Importantly, this move aligns with Fevara’s stated vision to be the global expert in extensive livestock supplements and its strategy of targeted investment in high-potential markets. Brazil sits at the top of that list, having recently overtaken the United States as the world’s largest beef producing country, according to USDA data published in January 2026.

Execution timeline and what to watch in 2026

The company expects production and distribution from the São Paulo facility to commence in Q2 next year. That gives several milestones to track: installation of low-moisture block capability, regulatory and operating readiness, and early sales momentum through the São Paulo and Macal channels.

The deferred consideration is explicitly tied to 2026 performance of the acquired mineral distribution business, which creates clear incentives for delivery. Investors should look for operational updates on product mix, state-by-state rollout into Goiás and Minas Gerais, and evidence that local manufacturing is expanding the addressable customer base.

Positives for investors

• Strategic fit: Adds local manufacturing in a priority market with scale and growth potential.
• Distribution synergy: Builds on the Macal acquisition to create a multi-state network.
• Focused products: Emphasis on specialist, high margin supplements that underpin profitability.
• Prudent structure: Majority of initial outlay tied to freehold property, with performance-based deferred consideration that is self-funding.
• Clear near-term catalyst: Production targeted in Q2 next year provides a tangible timeline.

Watch-outs and what’s not disclosed

• Financial uplift not disclosed: No revenue, EBITDA or profit figures provided for the acquired business.
• Deferred consideration amount not disclosed: We know timing and that it is performance-linked, but not the potential size.
• Capex and integration costs not disclosed: Adding low-moisture block capability may require investment and ramp-up time.
• Execution risk: Delivering customised products and building out distribution across multiple states requires strong operational discipline.

About Fevara at a glance

Fevara develops, manufactures and markets livestock supplements under recognised brands including Crystalyx, Horslic, Horslyx, Scotmin Nutrition, SmartLic, Tracesure Advanced and Macal. The Group is headquartered in Carlisle, Cumbria, with five manufacturing sites across the UK, US and Brazil and three operational joint ventures in Germany and the US. It serves customers in more than 20 countries and has been listed on the London Stock Exchange since 1972.

My take: a sensibly structured step-up in Brazil

This looks like a sensible and capital-light way to scale in a must-win market for Fevara. Buying a freehold-backed site, layering on specialist production, and plugging into an expanding, state-based distribution network is a coherent plan that plays to the Group’s strengths.

The lack of disclosed financials means we cannot size the near-term earnings impact, but the high margin product focus and performance-linked earn-out are both encouraging signals. Delivering Q2 next year production and visible traction in São Paulo, Mato Grosso do Sul, and the next two states will be the proof points to watch.

Net-net, a positive strategic move with clear execution milestones. If management hits the rollout timetable and proves the model across those initial states, Brazil could become a powerful growth engine for Fevara.